Cencora Inc. (COR)vsEDAP TMS SA (EDAP)
COR
Cencora Inc.
$321.57
+1.48%
HEALTHCARE · Cap: $61.36B
EDAP
EDAP TMS SA
$4.31
+0.23%
HEALTHCARE · Cap: $156.30M
Smart Verdict
WallStSmart Research — data-driven comparison
Cencora Inc. generates 449154% more annual revenue ($332.77B vs $74.07M). COR leads profitability with a 0.8% profit margin vs -41.7%. COR appears more attractively valued with a PEG of 0.68. COR earns a higher WallStSmart Score of 62/100 (C+).
COR
Buy62
out of 100
Grade: C+
EDAP
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.5%
Fair Value
$188.60
Current Price
$321.57
$132.97 premium
Margin of Safety
+41.7%
Fair Value
$8.41
Current Price
$4.31
$4.10 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 86 in profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Growing faster than its price suggests
Generating 2.4B in free cash flow
No standout strengths identified
Areas to Watch
0.8% margin — thin
Operating margin of 1.4%
Trading at 20.1x book value
Elevated debt levels
Trading at 8.3x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -124.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : COR
The strongest argument for COR centers on Return on Equity, Altman Z-Score, Market Cap. PEG of 0.68 suggests the stock is reasonably priced for its growth.
Bull Case : EDAP
Revenue growth of 13.9% demonstrates continued momentum.
Bear Case : COR
The primary concerns for COR are Profit Margin, Operating Margin, Price/Book. Debt-to-equity of 3.84 is elevated, increasing financial risk. Thin 0.8% margins leave little buffer for downturns.
Bear Case : EDAP
The primary concerns for EDAP are Price/Book, Market Cap, PEG Ratio.
Key Dynamics to Monitor
COR profiles as a value stock while EDAP is a turnaround play — different risk/reward profiles.
COR carries more volatility with a beta of 0.57 — expect wider price swings.
EDAP is growing revenue faster at 13.9% — sustainability is the question.
COR generates stronger free cash flow (2.4B), providing more financial flexibility.
Bottom Line
COR scores higher overall (62/100 vs 25/100). EDAP offers better value entry with a 41.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cencora Inc.
HEALTHCARE · MEDICAL DISTRIBUTION · USA
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
EDAP TMS SA
HEALTHCARE · MEDICAL DISTRIBUTION · USA
EDAP TMS SA, develops, produces, markets, distributes and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States and internationally. The company is headquartered in Lyon, France.
Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?